Mimedx Group Inc Stock Price, News & Analysis

MIMEDX has partnered with Gunze Medical to exclusively distribute EPIFIX in Japan, marking a significant move in the wound care market. This collaboration, announced on January 4, 2023, follows EPIFIX's regulatory approval and favorable reimbursement decision. Gunze Medical, backed by over 90 sales representatives, aims to leverage its existing clinician relationships to enhance awareness and sales. This partnership positions EPIFIX as the first and only amniotic tissue product approved in Japan for treating chronic wounds, targeting conditions like diabetic foot and venous leg ulcers.

MiMedx Group has appointed Ricci S. Whitlow as Chief Operating Officer, effective January 3, 2023. With over 30 years of experience in the MedTech industry, Whitlow is expected to enhance MIMEDX’s operational leadership in manufacturing, supply chain, and regulatory functions. Formerly President of Clinical Supply Services at Catalent, she aims to leverage her expertise to navigate complex regulatory changes and drive growth. Interim CEO Todd Newton emphasized the importance of this role for the company's future and its mission in placental biologics.

MiMedx Group, Inc. (Nasdaq: MDXG) has licensed exclusive rights to Turn Therapeutics’ antimicrobial technology, PermaFusion®, to enhance product development for wound and surgical recovery. This agreement aims to expedite the introduction of new biologic products, leveraging Turn's nanodroplet technology and antimicrobial properties. Furthermore, MiMedx is also acquiring commercial rights to Turn's FleX™ AM product, pending FDA clearance, expanding its portfolio in the wound care market.

Marietta, Ga., Nov. 10, 2022 – MiMedx Group (Nasdaq: MDXG), a placental biologics company, announced its participation in two upcoming investor conferences. Senior management will present at the Canaccord Genuity MedTech Forum on November 17, 2022, at 9:30 AM ET, and at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, also at 9:30 AM ET. Webcasts for both events will be available on the company's website. MiMedx specializes in developing and distributing placental tissue allografts for non-healing wounds and degenerative musculoskeletal conditions.

MiMedx Group reported third quarter net sales of $67.7 million, a 7.3% increase compared to the prior year. This growth was driven by the Surgical Recovery market and initial contributions from new products, AMNIOEFFECT™ and AXIOFILL™. However, the company also faced challenges, including a net loss of $8.4 million, up from $2.3 million the previous year. Operating expenses increased to $53.5 million, reflecting higher sales commissions and travel costs. Looking ahead, MiMedx anticipates fourth quarter sales of $73 to $76 million.

MiMedx Group, Inc. (MDXG) will report its third-quarter financial results for the period ended September 30, 2022, after market close on November 2, 2022. The company's management will host a conference call and webcast at 5:00 p.m. ET that day to discuss the results. MiMedx specializes in placental biologics and has supplied over two million allografts to address acute and chronic non-healing wounds. The company utilizes proprietary methods, including the PURION® process, to produce its allografts.

Marietta, GA, Oct. 4, 2022 – MiMedx Group, Inc. (NASDAQ: MDXG) has appointed Matt Notarianni as the new Head of Investor Relations, effective immediately. With over 15 years of experience in healthcare-focused financial services, Notarianni aims to enhance relationships with the investment community. Interim CEO K. Todd Newton expressed enthusiasm about Notarianni’s capabilities in amplifying the company’s story and engaging with investors. Jack Howarth will continue to support IR until his retirement at year-end.

MiMedx Group, Inc. (Nasdaq: MDXG) announced the launch of AXIOFILL, an extracellular matrix particulate derived from human placental tissue, aimed at the $1 billion surgical recovery market. This product stands out as the first human placental-derived particulate, providing a competitive edge over animal-based alternatives. The innovative PURION® technique preserves the natural tissue structure, enhancing its clinical utility for complex wounds. With AXIOFILL, MiMedx continues to focus on customer-driven innovation, reaffirming its commitment to meet the diverse needs of surgeons.

MiMedx Group (MDXG) has launched AMNIOEFFECT, a tri-layer PURION® processed human tissue allograft designed for diverse surgical applications. This new product enhances the Surgical Recovery portfolio and aims to penetrate the growing $1 billion surgical recovery market. Initial usage in over 50 cases has shown promising handling characteristics and effectiveness in complex procedures. Company President Rohit Kashyap noted strong surgeon interest, indicating AMNIOEFFECT addresses significant unmet needs in the field. The product supports healing by providing a biocompatible extracellular matrix.